DUBLIN–(BUSINESS WIRE)–The “Allergy Diagnostics and Therapeutics Market Forecast to 2033” has been added to ResearchAndMarkets.com’s offering.
The global allergy diagnostics and therapeutics market, valued at USD 34.42 billion in 2024, is projected to surge to USD 78 billion by 2033, reflecting a CAGR of 9.7% between 2025 and 2033. The market expansion is fueled by an increasing prevalence of allergies, technological advancements, and the introduction of innovative products, with a strong incline toward immunotherapy drugs.
Notably, the Global Allergy and Airways Patient Platform highlighted in November 2022 that 30-40% of the global population currently experiences allergies, a figure on the rise over the last two decades. Factors such as lifestyle changes and escalating pollution levels are significantly contributing to this trend. The advancement of therapeutically advanced drugs, like immunotherapy, which meet previously unmet medical needs, is anticipated to propel market growth further. A case in point is the U.S. FDA’s February 2024 approval of Xolair (omalizumab) for managing immunoglobulin E-mediated food allergies in certain age groups, a milestone in allergic reaction management.
Increased allergy prevalence remains a pivotal driver for the market’s growth trajectory. Chronic respiratory disorder risks are augmented by heightened exposure to air pollution and occupational environments. Urban areas, due to industrial activity, witness a higher incidence of allergies compared to rural locales, amplifying environmental contaminant exposure. WHO reported in January 2024 that one in four children and one in three adults suffer from seasonal allergies in the U.S., with approximately 6% burdened by food allergies, predominantly among black, Asian, and Hispanic communities. Concurrently, the Asthma and Allergy Foundation of America noted that 81 million Americans were affected by seasonal allergic rhinitis in 2021 alone.
The burgeoning demand for IVD testing underscores anticipated market growth through the forecast period. IVD blood tests efficiently diagnose various allergies and are gaining traction owing to their minimal invasiveness, cost-effectiveness, and user-friendliness. The introduction of affordable and efficient in vitro diagnostic tests, increased lab automation, and surging reagent rental agreements further catalyze market expansion.
Global Allergy Diagnostics and Therapeutic Market Report Segmentation
This report offers revenue growth projections and trend analyses within each sub-segment from 2021 to 2030, segmented by type, allergen type, test type, and region:
Type Outlook (Revenue, USD Million, 2021-2033)
- Diagnostics
- Therapeutics
Allergen Type Outlook (Revenue, USD Million, 2021-2033)
- Food
- Inhaled
- Drug
- Others
Test Type Outlook (Revenue, USD Million, 2021-2033)
- In Vivo Tests
- In Vitro Tests
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa (MEA)
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and drive strategic business decisions.
Report Deliverables
- Market intelligence for effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts
- Competition strategy and market share analysis
- Product innovation listings to stay ahead of the curve
Key Attributes
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2024-2033 |
| Estimated Market Value (USD) in 2024 | $34.42 Billion |
| Forecasted Market Value (USD) by 2033 | $78 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
The companies profiled in this Allergy Diagnostics and Therapeutics market report include:
- R-Biopharm AG
- DASIT Group S.p.A.
- EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)
- AESKU.GROUP GmbH
- bioMerieux
- Siemens Healthcare GmbH
- Stallergenes Greer
- HYCOR Biomedical
- Minaris Medical America, Inc.
- Omega Diagnostics Group PLC
- Lincoln Diagnostics, Inc.
- HOB Biotech Group Corp., Ltd.
- Danaher
- Alcon
- AbbVie, Inc.
- Sanofi
- Allergy Therapeutics
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Astellas Pharma Inc.
- Epigenomics AG
For more information about this report visit https://www.researchandmarkets.com/r/jrhc50
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900